Non-Hodgkin’s lymphoma (NHL) is a common malignant tumor of the hematological system, which is not uncommon in all countries in the world, and its incidence has been on the rise in recent years. Conventional treatment includes chemotherapy, radiotherapy, immunotherapy, etc. The treatment effect is still satisfactory. However, a certain proportion of relapsed drug-resistant patients has become a difficult clinical management problem. The anti-CD20 antigen monoclonal antibody Meroval is the first monoclonal antibody approved by the FDA for lymphoma treatment, which is the most important progress in the treatment of low-grade malignant lymphoma in the 1990s. It achieves the treatment of lymphoma through immune mechanism, anti-tumor cell proliferation and prompting apoptosis of tumor cells. Clinical trials in Europe and the United States have shown that Merova has good efficacy in B-cell NHL, with an efficiency of 40% to 50% for monotherapy; the efficiency of Merova combined with chemotherapy is over 90%. In 1998, it was approved by FDA for marketing in the United States.